- Moving sharply higher on the day are shares of NeoStem (NBS +11.7%).
- Helping the cause is Aegis' Ram Selvaraju who is "enthused about the completion of enrollment [in PreSERVE], given the lengthy period of time that this trial has taken to accrue the requisite number of patients."
- The analyst remains "confident that the AMR-001 Phase 2 study has a high likelihood of success."
- Price target hiked to $23 (from $21). For what it's worth, that represents upside of 240% from Tuesday's close.
Aegis sees big upside for NeoStem on AMR-001 potential
Jan 2 2014, 12:45 ET